Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 9:09 AM ET


Company Overview of Merck Canada Inc.

Company Overview

Merck Canada Inc. researches, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and consumer care and animal health products. The company offers various vaccines for the prevention of rare diseases, such as measles and mumps, shingles, and cervical cancer; prescription products in various therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, and women's health; and consumer healthcare products that help to prevent or treat various common conditions, including allergies, sun care, foot care, nasal and cough/cold care, digestive care, and more. It also offers veterinary medicines, including va...

16750 Trans Canada Highway

Kirkland, QC H9H 4M7


Founded in 1982





Key Executives for Merck Canada Inc.

President and Managing Director
President of Merck Research Laboratories
Age: 56
Vice President of Human Resources
Compensation as of Fiscal Year 2015.

Merck Canada Inc. Key Developments

Merck Canada Inc.'s KEYTRUDA (pembrolizumab) Receives Conditional Approval in Canada for the Treatment of Advanced Melanoma

Merck Canada Inc. announced that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer1. It is the first of a new class of therapies called anti-PD-1s approved in Canada. Among the different types of skin cancer, melanoma has the metastatic potential2. KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor3. The product has been approved in Canada under the Notice of Compliance with Conditions (NOC/c) policy on the basis of promising evidence of clinical effectiveness and pending the results of trials to verify its anticipated benefit.

Merck Canada Inc Appoints Chirfi Guindo to President and Managing Director

Merck Canada Inc. announced the appointment of Chirfi Guindo to President and Managing Director.

Merck Canada Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 03:45 PM

Merck Canada Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 03:45 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada. Speakers: Stephen Xanthoudakis.

Similar Private Companies By Industry

Company Name Region
Merial Canada, Inc. Americas
IGY Immune Technologies & Life Sciences Inc. Americas
Bio-K Plus International Inc. Americas
CardioMetabolics Inc. Americas
Evergreen Medicinal Supply Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Merck Canada Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at